

Single-Dose Nirsevimab for Prevention of RSV in Preterm

New England Journal of Medicine

383, 415-425

DOI: [10.1056/nejmoa1913556](https://doi.org/10.1056/nejmoa1913556)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity. <i>Vaccines</i> , 2020, 8, 607.	2.1	8
2	Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines. <i>Vaccines</i> , 2020, 8, 672.	2.1	41
3	Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era. <i>Seminars in Immunology</i> , 2020, 50, 101427.	2.7	31
4	An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 596908.	2.2	8
5	Implications of gestational age at antenatal care attendance on the successful implementation of a maternal respiratory syncytial virus (RSV) vaccine program in coastal Kenya. <i>BMC Public Health</i> , 2020, 20, 1723.	1.2	5
6	Disarming the Respiratory Syncytial Virus. <i>New England Journal of Medicine</i> , 2020, 383, 487-488.	13.9	4
7	Phase 1â€”2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2320-2332.	13.9	1,000
8	Palivizumab for preventing respiratory syncytial virus (RSV) infection in children. <i>The Cochrane Library</i> , 0, , .	1.5	2
9	Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017â”2018 INFORM-RSV Study. <i>Journal of Clinical Microbiology</i> , 2020, 59, .	1.8	52
10	Live-attenuated Respiratory Syncytial Virus Vaccines: Time for the Next Step. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 538-539.	2.5	6
11	Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 419-441.	2.0	9
12	The burden of respiratory syncytial virus infections among children with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28759.	0.8	1
13	Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. <i>Biomedical Journal</i> , 2021, 44, 7-17.	1.4	38
14	Burden of Respiratory Syncytial Virus Infection During the First Year of Life. <i>Journal of Infectious Diseases</i> , 2021, 223, 811-817.	1.9	26
15	A Phase 1 Randomized, Doubleâ€”Blind, Placeboâ€”Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MKâ€”1654 in Healthy Adults. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 556-566.	0.8	29
16	Protective antibodies against human parainfluenza virus type 3 infection. <i>MAbs</i> , 2021, 13, 1912884.	2.6	13
17	RSV Vaccines and Monoclonal Antibodies in Development. , 2021, , 293-296.		0
18	Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1867-1872.	1.4	14

#	ARTICLE	IF	CITATIONS
19	Respiratory infections. , 2021, , 244-347.		0
20	Clinical impact of respiratory syncytial virus infection on children hospitalized for pertussis. BMC Infectious Diseases, 2021, 21, 161.	1.3	2
21	Nirsevimab reduces medically attended RSV-associated lower respiratory tract infection and hospitalisations in healthy pre-term infants. Archives of Disease in Childhood: Education and Practice Edition, 2021, , edpract-2020-321141.	0.3	2
22	Epidemiology of respiratory syncytial virus in a community birth cohort of infants in the first 2 years of life. European Journal of Pediatrics, 2021, 180, 2125-2135.	1.3	12
23	Risk Factors for Respiratory Syncytial Virus Lower Respiratory Tract Infections: Evidence from an Indonesian Cohort. Viruses, 2021, 13, 331.	1.5	2
24	Respiratory syncytial virus subtype circulation and associated disease severity at an Australian paediatric referral hospital, 2014â€“2018. Journal of Paediatrics and Child Health, 2021, 57, 1190-1195.	0.4	9
25	Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering. BioDrugs, 2021, 35, 147-157.	2.2	24
26	The Fifth International Neonatal and Maternal Immunization Symposium (INMIS 2019): Securing Protection for the Next Generation. MSphere, 2021, 6, .	1.3	4
27	Saudi expertsâ€™ recommendation for RSV prophylaxis in the era of COVID-19. Journal of King Abdulaziz University, Islamic Economics, 2021, 42, 355-362.	0.5	4
28	The Future of Respiratory Syncytial Virus Disease Prevention and Treatment. Infectious Diseases and Therapy, 2021, 10, 47-60.	1.8	68
29	Early Life RSV: Can Vaccines Help Fix Societal Ills?. Pediatrics, 2021, 147, e2020038356.	1.0	0
30	Family and Child Risk Factors for Early-Life RSV Illness. Pediatrics, 2021, 147, .	1.0	24
31	Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017. Human Vaccines and Immunotherapeutics, 2022, 18, 1-7.	1.4	22
32	Epidemiology and Seasonality of Childhood Respiratory Syncytial Virus Infections in the Tropics. Viruses, 2021, 13, 696.	1.5	12
33	Burden of respiratory syncytial virus bronchiolitis on the Dutch pediatric intensive care units. European Journal of Pediatrics, 2021, 180, 3141-3149.	1.3	19
34	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell, 2021, 184, 1821-1835.e16.	13.5	180
35	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity, 2021, 54, 769-780.e6.	6.6	37
37	Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?. International Journal of Molecular Sciences, 2021, 22, 3703.	1.8	18

#	ARTICLE	IF	CITATIONS
38	Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses. <i>Viruses</i> , 2021, 13, 1023.	1.5	10
39	A Vulnerable, Membrane-Proximal Site in Human Respiratory Syncytial Virus F Revealed by a Prefusion-Specific Single-Domain Antibody. <i>Journal of Virology</i> , 2021, 95, .	1.5	8
40	Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures. <i>MSphere</i> , 2021, 6, .	1.3	14
41	RSV genomic diversity and the development of a globally effective RSV intervention. <i>Vaccine</i> , 2021, 39, 2811-2820.	1.7	5
42	Preventing respiratory syncytial virus (RSV) disease in children. <i>Science</i> , 2021, 372, 686-687.	6.0	22
43	Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, S35-S39.	1.1	21
44	Respiratory Syncytial Virus (RSV)â€“Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. <i>Journal of Infectious Diseases</i> , 2022, 225, 1189-1196.	1.9	16
46	The burden of Respiratory Syncytial Virus (RSV) infection in the Middle East and North Africa (MENA) region across age groups: A systematic review. <i>Vaccine</i> , 2021, 39, 3803-3813.	1.7	2
47	Prophylaxis against respiratory syncytial virus in high-risk infants. , 2021, , 361-371.		1
48	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	13.5	309
49	Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand. <i>Vaccine</i> , 2021, 39, 4383-4390.	1.7	3
50	Immunologic and Virologic Factors Associated With Hospitalization in Human Immunodeficiency Virusâ€“Exposed, Uninfected Infants in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, 1089-1096.	2.9	21
51	Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. <i>European Journal of Internal Medicine</i> , 2021, 89, 3-9.	1.0	19
52	Evaluation of a standardised protocol to measure the disease burden of respiratory syncytial virus infection in young children in primary care. <i>BMC Infectious Diseases</i> , 2021, 21, 705.	1.3	9
53	Utility of the Global Respiratory Severity Score for predicting the need for respiratory support in infants with respiratory syncytial virus infection. <i>PLoS ONE</i> , 2021, 16, e0253532.	1.1	5
55	Respiratory syncytial virus and influenza hospitalizations in Danish children 2010â€“2016. <i>Vaccine</i> , 2021, 39, 4126-4134.	1.7	8
56	Antimicrobial immunotherapeutics: past, present and future. <i>Emerging Topics in Life Sciences</i> , 2021, 5, 609-628.	1.1	1
57	Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	6

#	ARTICLE	IF	CITATIONS
58	A Multivariate Age-Structured Stochastic Model with Immunization Strategies to Describe Bronchiolitis Dynamics. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7607.	1.2	0
59	Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic. <i>Eurosurveillance</i> , 2021, 26, .	3.9	57
60	Increasing burden of viral bronchiolitis in the pediatric intensive care unit; an observational study. <i>Journal of Critical Care</i> , 2022, 68, 165-168.	1.0	13
61	Update in Pediatrics 2020. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 274-284.	2.5	0
62	Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. <i>Frontiers in Immunology</i> , 2021, 12, 708939.	2.2	8
63	Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions. <i>Vaccine</i> , 2021, 39, 5037-5045.	1.7	17
64	Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. <i>Nature Communications</i> , 2021, 12, 5125.	5.8	16
65	Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein. <i>Journal of Virology</i> , 2021, 95, e0048521.	1.5	7
67	Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities. <i>Vaccines</i> , 2021, 9, 961.	2.1	24
68	Recalibrating public health expectations of respiratory syncytial virus lower respiratory tract illness prevention on chronic respiratory disease. <i>Vaccine</i> , 2021, 39, 5257-5258.	1.7	3
70	The impact of childhood RSV infection on children's and parents' quality of life: a prospective multicenter study in Spain. <i>BMC Infectious Diseases</i> , 2021, 21, 924.	1.3	18
71	Cord blood respiratory syncytial virus antibodies and respiratory health in first 5 years of life. <i>Pediatric Pulmonology</i> , 2021, 56, 3942-3951.	1.0	4
72	Risk Factors for Respiratory Syncytial Virus-Associated Community Deaths in Zambian Infants. <i>Clinical Infectious Diseases</i> , 2021, 73, S187-S192.	2.9	10
73	Global Respiratory Syncytial Virus-Related Infant Community Deaths. <i>Clinical Infectious Diseases</i> , 2021, 73, S229-S237.	2.9	29
74	Maternal RSV vaccine development. Where to from here?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4542-4548.	1.4	13
75	Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities. <i>Vaccine</i> , 2021, 39, 5490-5498.	1.7	7
76	A systematic review on global RSV genetic data: Identification of knowledge gaps. <i>Reviews in Medical Virology</i> , 2022, 32, e2284.	3.9	19
77	Implementation strategies for passive respiratory syncytial virus immunisation. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1200-1201.	4.6	4

#	ARTICLE	IF	CITATIONS
78	Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1303-1312.	4.6	37
79	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 1111-1120.	5.2	38
80	Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada. <i>EClinicalMedicine</i> , 2021, 41, 101141.	3.2	14
81	Acute viral bronchiolitis. , 2021, , 267-273.		0
82	Childhood pneumonia in Sub-Saharan Africa: Still a challenge. , 0, 2, 1-3.		4
84	Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies. <i>International Journal of Biological Sciences</i> , 2021, 17, 4073-4091.	2.6	31
85	RSV: perspectives to strengthen the need for protection in all infants. <i>Emerging Themes in Epidemiology</i> , 2021, 18, 15.	1.2	16
86	Respiratory Viruses in Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 2146.	1.5	3
87	Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine. <i>Journal of Infectious Diseases</i> , 2022, 225, 2077-2086.	1.9	16
88	Approaching the End of the Era of Uncontrolled Respiratory Syncytial Virus Disease. <i>Journal of Infectious Diseases</i> , 2021, 223, 737-739.	1.9	2
89	Respiratory Syncytial Virusâ€“Associated Hospital Admissions and Bed Days in Children <5 Years of Age in 7 European Countries. <i>Journal of Infectious Diseases</i> , 2022, 226, S22-S28.	1.9	19
93	Respiratory Syncytial Virus-attributable Deaths in a Major Pediatric Hospital in New South Wales, Australia, 1998â€“2018. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, 186-191.	1.1	2
95	Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model. <i>Infectious Diseases and Therapy</i> , 2022, 11, 277-292.	1.8	14
96	Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. <i>The Cochrane Library</i> , 2021, 2021, CD013757.	1.5	28
97	MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 778829.	2.2	2
98	Role of age and birth month in infants hospitalized with RSVâ€“confirmed disease in the Valencia Region, Spain. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 328-339.	1.5	9
99	TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO). <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4299-4327.	1.4	0
100	Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis. <i>EBioMedicine</i> , 2021, 73, 103651.	2.7	25

#	ARTICLE	IF	CITATIONS
101	New preventive strategies for respiratory syncytial virus infection in children. <i>Current Opinion in Virology</i> , 2021, 51, 216-223.	2.6	4
102	Developing a prediction model to estimate the true burden of respiratory syncytial virus (RSV) in hospitalised children in Western Australia. <i>Scientific Reports</i> , 2022, 12, 332.	1.6	212
103	The Long-Term Healthcare Utilization and Economic Burden of RSV Infection in Infants<5 Years in Japan: A Propensity Score Matched Case Control Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
104	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. <i>Science Translational Medicine</i> , 2022, 14, eabl8124.	5.8	143
105	Modeling viral infection with tissue engineering: COVID-19 and the next outbreaks. , 2022, , 647-667.		1
106	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment â€“ Meeting report from an isirv-WHO virtual conference. <i>Antiviral Research</i> , 2022, 197, 105227.	1.9	19
107	Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 548-551.	3.0	8
108	Hospital Charges Associated With Critical Bronchiolitis From 2009 to 2019*. <i>Pediatric Critical Care Medicine</i> , 2022, 23, 171-180.	0.2	17
109	HRSV prefusion-F protein with Adju-Phos adjuvant induces long-lasting Th2-biased immunity in mice. <i>PLoS ONE</i> , 2022, 17, e0262231.	1.1	3
110	Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children in 2019: A Systematic Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
111	Deaths from RSV in young infantsâ€™the hidden community burden. <i>The Lancet Global Health</i> , 2022, 10, e169-e170.	2.9	7
112	Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project. <i>The Lancet Global Health</i> , 2022, 10, e269-e277.	2.9	19
113	Human Antibodies for Viral Infections. <i>Annual Review of Immunology</i> , 2022, 40, 349-386.	9.5	23
114	Disease burden of respiratory syncytial virus infection in the pediatric population in Japan. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 146-157.	0.8	3
115	Immunopathology of RSV: An Updated Review. <i>Viruses</i> , 2021, 13, 2478.	1.5	38
116	Nirsevimab: An Extended Half-life Monoclonal Antibody for the Prevention of Infant Respiratory Syncytial Virus Infection. <i>US Respiratory & Pulmonary Diseases</i> , 2021, 6, 38.	0.2	0
117	Global Disease Burden of Respiratory Syncytial Virus in Preterm Children in 2019: A Systematic Review and Individual Participant Data Meta-Analysis Protocol. <i>Journal of Infectious Diseases</i> , 2022, 226, S135-S141.	1.9	3
118	WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants â€“ Key considerations for global use. <i>Vaccine</i> , 2022, 40, 3506-3510.	1.7	20

#	ARTICLE	IF	CITATIONS
120	Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018. JAMA Network Open, 2022, 5, e220527.	2.8	81
121	Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children. Journal of Infectious Diseases, 2022, 226, S95-S101.	1.9	15
122	[Translated article] Where is Respiratory Syncytial Virus Hidden?. Archivos De Bronconeumologia, 2022, 58, T298-T298.	0.4	1
123	Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. New England Journal of Medicine, 2022, 386, 837-846.	13.9	328
124	Protein and Peptide Substances in the Treatment of Respiratory Syncytial Infection: Current State. Molecules, 2022, 27, 2263.	1.7	3
125	Chinese expert consensus on immunoprophylaxis of common respiratory pathogens in children (2021) Tj ETQq1 1 0.784314 1rgBT /Over 0.6	0.6	1
126	Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. New England Journal of Medicine, 2022, 386, 892-894.	13.9	68
127	Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159139.	1.2	18
128	Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials. Journal of Clinical Epidemiology, 2022, 147, 11-20.	2.4	2
129	Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). Expert Opinion on Investigational Drugs, 2022, 31, 23-29.	1.9	13
130	Respiratory Syncytial Virus Resurgence in Italy: The Need to Protect All Neonates and Young Infants. International Journal of Environmental Research and Public Health, 2022, 19, 380.	1.2	13
132	COVID-19 Lesson for Respiratory Syncytial Virus (RSV): Hygiene Works. Children, 2021, 8, 1144.	0.6	17
133	A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine. Journal of Infectious Diseases, 2022, 225, 1357-1366.	1.9	38
134	Respiratory syncytial virus: promising progress against a leading cause of pneumonia. The Lancet Global Health, 2021, 9, e1644-e1645.	2.9	14
135	Neonatal Immune Responses to Respiratory Viruses. Frontiers in Immunology, 2022, 13, 863149.	2.2	7
137	Seasonality of respiratory syncytial virus and its association with meteorological factors in 13 European countries, week 40 2010 to week 39 2019. Eurosurveillance, 2022, 27, .	3.9	18
138	Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis. Journal of Infectious Diseases, 2022, 226, S225-S235.	1.9	15
139	Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States. Journal of Infectious Diseases, 2022, 226, S293-S299.	1.9	4

#	ARTICLE	IF	CITATIONS
140	RSV Prevention in All Infants: Which Is the Most Preferable Strategy?. <i>Frontiers in Immunology</i> , 2022, 13, 880368.	2.2	50
142	Prefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy. <i>New England Journal of Medicine</i> , 2022, 386, 1615-1626.	13.9	78
144	Identifying the Target Population for Primary Respiratory Syncytial Virus Two-Step Prevention in Infants: Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN). <i>Vaccines</i> , 2022, 10, 729.	2.1	0
145	Maternal immune protection against infectious diseases. <i>Cell Host and Microbe</i> , 2022, 30, 660-674.	5.1	18
146	Issues Associated With Respiratory Syncytial Virus Immunoprophylaxis and Immunization. <i>Pediatric Emergency Care</i> , 2022, 38, e1340-e1341.	0.5	0
147	Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. <i>Lancet</i> , The, 2022, 399, 2047-2064.	6.3	445
148	Pranlukast treatment and the use of respiratory support in infants with respiratory syncytial virus infection. <i>PLoS ONE</i> , 2022, 17, e0269043.	1.1	1
149	Establishment and application of a lethal model of an HRSV-Long variant strain in BALB/c mice. <i>Experimental Animals</i> , 2022, , .	0.7	1
150	Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings. <i>Journal of Infectious Diseases</i> , 2022, 226, 374-385.	1.9	10
151	Respiratory Syncytial Virus in Pregnant Women: Systematic Review and Meta-Analysis. <i>Women</i> , 2022, 2, 147-160.	0.5	2
152	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	7
153	Antibodies to combat viral infections: development strategies and progress. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 676-696.	21.5	68
154	Palivizumab Use in the NICU: 1999–2020. <i>Pediatrics</i> , 0, , .	1.0	0
155	RSV disease in infants and young children: Can we see a brighter future?. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	17
157	Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	8
159	Age and respiratory syncytial virus etiology in bronchiolitis clinical outcomes. , 2022, 1, 91-98.		5
160	Determinants of RSV epidemiology following suppression through pandemic contact restrictions. <i>Epidemics</i> , 2022, 40, 100614.	1.5	17
161	Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612211121.	1.1	3

#	ARTICLE	IF	CITATIONS
162	Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9604.	1.8	9
163	Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model. <i>Journal of Infectious Diseases</i> , 2022, 226, S282-S292.	1.9	27
164	The assessment of future RSV immunizations: How to protect all infants?. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	10
165	The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis. <i>Journal of Infectious Diseases</i> , 2022, 226, S143-S147.	1.9	9
166	Immunization of preterm infants: current evidence and future strategies to individualized approaches. <i>Seminars in Immunopathology</i> , 2022, 44, 767-784.	2.8	7
167	Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies. <i>Expert Review of Vaccines</i> , 2022, 21, 1523-1531.	2.0	7
168	Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. <i>Lancet Infectious Diseases</i> , The, 2023, 23, e2-e21.	4.6	138
169	Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions. <i>Journal of Paediatrics and Child Health</i> , 2022, 58, 1741-1746.	0.4	14
171	From animal studies into clinical trials: the relevance of animal models to develop vaccines and therapies to reduce disease severity and prevent hRSV infection. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 1237-1259.	2.5	3
172	Bronchiolitis therapies and misadventures. <i>Paediatric Respiratory Reviews</i> , 2023, 46, 49-56.	1.2	1
173	Vaccination, or how to alleviate the crisis in pediatric emergency units. <i>Infectious Diseases Now</i> , 2022, , .	0.7	1
174	The role of birth month in the burden of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in Croatia. <i>PLoS ONE</i> , 2022, 17, e0273962.	1.1	3
175	The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States. <i>Vaccine</i> , 2022, 40, 6064-6073.	1.7	2
176	Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab. <i>American Journal of Perinatology</i> , 2022, 39, S7-S13.	0.6	1
177	Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4
178	Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18â€“50 Years and RSV-Seropositive Children 12â€“24 Months. <i>Journal of Infectious Diseases</i> , 2022, 227, 71-82.	1.9	11
179	Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
180	A Candidate Therapeutic Monoclonal Antibody Inhibits Both HRSV and HMPV Replication in Mice. <i>Biomedicines</i> , 2022, 10, 2516.	1.4	3

#	ARTICLE	IF	CITATIONS
181	Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine and Growth Factor Reviews, 2022, 68, 37-53.	3.2	23
182	Respiratory Syncytial Virus: An Uncommon Cause of Febrile Seizuresâ€”Results from a Systematic Review and Meta-Analysis. Pediatric Reports, 2022, 14, 464-478.	0.5	5
184	Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood. Jornal De Pediatria, 2023, 99, S4-S11.	0.9	10
185	The Long-Term Healthcare Utilization and Economic Burden of RSV Infection in Children â‰¥5 Years in Japan: Propensity Score Matched Cohort Study. ClinicoEconomics and Outcomes Research, 0, Volume 14, 699-714.	0.7	3
186	RSV: UK to examine whether to offer monoclonal antibody routinely to all babies. BMJ, The, 0, , o2725.	3.0	4
187	Passive Immunization. , 2023, , 38-44.e2.		0
188	Respiratory Syncytial Virus. , 2023, , 1185-1188.e1.		0
189	Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study. Value in Health, 2023, 26, 508-518.	0.1	9
190	Evaluating the impact of Respiratory Syncytial Virus immunisation strategies on antibiotic use and drug resistant bacterial infections in England. Wellcome Open Research, 0, 7, 286.	0.9	0
191	Prematurity-associated wheeze: current knowledge and opportunities for further investigation. Pediatric Research, 2023, 94, 74-81.	1.1	0
192	La profilassi dellâ€™infezione da virus respiratorio sinciziale: dal palivizumab al nirsevimab. Medico E Bambino, 2022, 41, 632-639.	0.1	3
193	Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities. Infectious Diseases and Therapy, 2023, 12, 317-332.	1.8	6
194	Neutralizing and Epitope-Specific Antibodies against Respiratory Syncytial Virus in Maternal and Cord Blood Paired Samples. Viruses, 2022, 14, 2702.	1.5	0
195	A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine. Science Translational Medicine, 2022, 14, .	5.8	13
196	Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge. Vaccines, 2022, 10, 2078.	2.1	4
197	RSV immunisation: lessons from the COVID-19 pandemic. The Lancet Child and Adolescent Health, 2023, , .	2.7	1
198	Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study. The Lancet Child and Adolescent Health, 2023, 7, 171-179.	2.7	39
199	Immunisation schedule of the Spanish Association of Paediatrics: 2023 Recommendations. Anales De PediatrÃa (English Edition), 2023, 98, 58.e1-58.e10.	0.1	3

#	ARTICLE	IF	CITATIONS
200	Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. <i>The Lancet Child and Adolescent Health</i> , 2023, 7, 180-189.	2.7	72
202	Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV). <i>Pathogens</i> , 2023, 12, 154.	1.2	14
204	Prevalence of infectious diseases in preterm infants: a 2-year follow-up from the Japan Environment and Children's Study. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
205	Nirsevimab: First Approval. <i>Drugs</i> , 2023, 83, 181-187.	4.9	29
206	Biochemistry of the Respiratory Syncytial Virus L Protein Embedding RNA Polymerase and Capping Activities. <i>Viruses</i> , 2023, 15, 341.	1.5	1
207	Model-estimated impacts of pediatric respiratory syncytial virus prevention programs in Mali on asthma prevalence. , 2023, 2, 100092.		0
208	The therapeutic age of the neonatal Fc receptor. <i>Nature Reviews Immunology</i> , 2023, 23, 415-432.	10.6	28
209	Impact of breastfeeding on the incidence and severity of respiratory syncytial virus (RSV)-associated acute lower respiratory infections in infants: a systematic review highlighting the global relevance of primary prevention. <i>BMJ Global Health</i> , 2023, 8, e009693.	2.0	11
210	The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein. <i>Vaccines</i> , 2023, 11, 382.	2.1	10
211	UPDATE - 2022 Italian guidelines on the management of bronchiolitis in infants. <i>Italian Journal of Pediatrics</i> , 2023, 49, .	1.0	28
212	Prematurity and BPD: what general pediatricians should know. <i>European Journal of Pediatrics</i> , 2023, 182, 1505-1516.	1.3	8
213	Cross-protective antibodies against common endemic respiratory viruses. <i>Nature Communications</i> , 2023, 14, .	5.8	6
214	Case 19. A One-Year-Old Girl with Fever, Cough, and Posttussive Vomiting: Respiratory Syncytial Virus Infection. , 2023, , 93-97.		0
215	Nirsevimab: Towards universal child immunization against respiratory syncytial virus. <i>Vacunas (English Edition)</i> , 2023, 24, 68-73.	0.3	1
216	Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children. <i>JAMA Network Open</i> , 2023, 6, e230023.	2.8	24
217	Respiratory Syncytial Virus Prevention through Monoclonal Antibodies: A Cross-Sectional Study on Knowledge, Attitudes, and Practices of Italian Pediatricians. <i>Pediatric Reports</i> , 2023, 15, 154-174.	0.5	4
218	RSV through the COVID-19 pandemic: Burden, shifting epidemiology, and implications for the future. <i>Pediatric Pulmonology</i> , 2023, 58, 1631-1639.	1.0	12
219	Treatment activity of budesonide-loaded poly(lactic-co-glycolic acid) microspheres in infant bronchiolitis. <i>Materials Express</i> , 2022, 12, 1488-1492.	0.2	0

#	ARTICLE	IF	CITATIONS
220	Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 1143-1149.	1.3	4
221	Nirsevimab come immunoprofilassi universale dell'™infezione da virus respiratorio sinciziale?. <i>Medico E Bambino</i> , 2023, 42, 155-158.	0.1	2
222	Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 856-866.	4.6	17
223	Estimates of the national burden of respiratory syncytial virus in Kenyan children aged under 5 years, 2010-2018. <i>BMC Medicine</i> , 2023, 21, .	2.3	5
224	Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa. <i>BMC Medicine</i> , 2023, 21, .	2.3	8
225	The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	3
226	Early online. <i>South African Medical Journal</i> , 0, , .	0.2	0
227	Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	14
228	New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus. <i>Infection and Drug Resistance</i> , 0, Volume 16, 2061-2074.	1.1	2
229	Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries. <i>BMC Medicine</i> , 2023, 21, .	2.3	5
230	Respiratory syncytial virus infection in COVID-19 times: Trick or threat?. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2023, , .	0.2	0
231	Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants. <i>Journal of Medical Economics</i> , 2023, 26, 630-643.	1.0	7
232	Pneumococcal conjugate vaccines are protective against respiratory syncytial virus-hospitalisations in infants: a population-based observational study. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	2
243	Respiratory Syncytial Virus Infection: An Update. <i>Indian Journal of Pediatrics</i> , 2023, 90, 1245-1253.	0.3	5
255	Respiratory syncytial virus infection and novel interventions. <i>Nature Reviews Microbiology</i> , 2023, 21, 734-749.	13.6	23
256	Spatial resolution of virus replication: RSV and cytoplasmic inclusion bodies. <i>Advances in Virus Research</i> , 2023, , .	0.9	0
261	Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies. , 2023, , 998-1004.e5.		0
263	Passive Immunization. , 2023, , 100-112.e11.		0

#	ARTICLE	IF	CITATIONS
271	The road to approved vaccines for respiratory syncytial virus. <i>Npj Vaccines</i> , 2023, 8, .	2.9	6
275	RSV. , 2023, , 197-199.		0
282	Progress at last against RSV. <i>Nature Medicine</i> , 2023, 29, 2143-2143.	15.2	1
330	Update in Pediatric Infectious Disease. , 2023, , 481-502.		0